Nancy Reau to Risk Assessment
This is a "connection" page, showing publications Nancy Reau has written about Risk Assessment.
Connection Strength
0.237
-
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018 10; 68(4):1298-1307.
Score: 0.133
-
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
Score: 0.079
-
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
Score: 0.026